Related Experiment Videos
B lymphocytes as antigen-presenting cell-based genetic vaccines
Maurizio Zanetti1, Paola Castiglioni, Marta Rizzi
1The Department of Medicine and Cancer Center, University of California, San Diego, La Jolla, CA 92093-0837, USA. mzanetti@ucsd.edu
Immunological Reviews
|July 6, 2004
Summary
Genetically programmed B lymphocytes overcome low immunogenicity, offering a novel DNA vaccine strategy. This approach induces robust T-cell immunity and protection against viral challenges with a single injection.
Area of Science:
- Immunology
- Vaccinology
- Biotechnology
Background:
- Plasmid DNA inoculation for immunization suffers from low immunogenicity, hindering effective DNA vaccine development.
- Conventional methods require facilitators for DNA uptake, limiting spontaneous transfection.
Purpose of the Study:
- To propose and validate genetically programmed B lymphocytes as antigen-presenting cell (APC) vaccines.
- To address the challenge of low immunogenicity in DNA vaccine strategies.
Main Methods:
- Demonstration of spontaneous plasmid DNA uptake by mature B lymphocytes (spontaneous lymphocyte transgenesis).
- Transgenic B lymphocytes were engineered into functional APCs with upregulated costimulatory molecules and endogenous antigen synthesis.
- Evaluation of transgenic B lymphocytes as immunogens in mice.
Main Results:
- Transgenic B lymphocytes induced robust and long-lasting T-cell immunity after a single intravenous injection.
- Effective immunity and protection against lethal viral challenge were achieved with a low dose (3 x 10^2) of transgenic lymphocytes.
- The approach leverages targeting secondary lymphoid organs and sustained antigen presentation.
Conclusions:
- Genetically programmed B lymphocytes represent a promising new vaccine platform overcoming DNA vaccine limitations.
- The strategy offers advantages in targeting lymphoid organs and utilizing low antigen doses for potent immune responses.
- This method facilitates spontaneous lymphocyte transgenesis and functional APC development for enhanced vaccine efficacy.